<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>283</serviceExecutionTime><Drug id="91822"><DrugName>house dust mites immunotherapy (allergic rhinitis), Stallergenes</DrugName><DrugNamesKey><Name id="43037811">Alustal</Name><Name id="43037810">Alustal Rapid</Name></DrugNamesKey><DrugSynonyms><Name><Value>house dust mites immunotherapy (allergic rhinitis), Stallergenes</Value></Name><Name><Value>Alustal Rapid</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Alustal</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19274">Stallergenes SA</CompanyOriginator><CompaniesPrimary><Company id="19274">Stallergenes SA</Company></CompaniesPrimary><CrossReferences><SourceEntity id="19274" type="Company"><TargetEntity id="4295868053" type="organizationId">Stallergenes SA</TargetEntity></SourceEntity><SourceEntity id="1107" type="ciIndication"><TargetEntity id="10039085" type="MEDDRA"/><TargetEntity id="-600684678" type="omicsDisease"/><TargetEntity id="298" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Allergic rhinitis - Spain - Apr-2010</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1107">Allergic rhinitis</Indication></IndicationsPrimary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><LastModificationDate>2016-04-07T10:08:24.000Z</LastModificationDate><ChangeDateLast>2016-04-07T00:00:00.000Z</ChangeDateLast><AddedDate>2014-07-07T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19274" linkType="Company"&gt;Stallergenes&lt;/ulink&gt; (now a subsidiary of &lt;ulink linkID="1116433" linkType="Company"&gt;Stallergenes Greer&lt;/ulink&gt;) had developed and launched house dust mites (Dermatophagoides pteronyssinus + D farinae) immunotherapy (Alustal Rapid; Alustal)  for sc treatment of allergic rhinitis [&lt;ulink linkID="1426523" linkType="Reference"&gt;1426523&lt;/ulink&gt;], [&lt;ulink linkID="1566249" linkType="Reference"&gt;1566249&lt;/ulink&gt;], [&lt;ulink linkID="1714787" linkType="Reference"&gt;1714787&lt;/ulink&gt;]. By April 2010, this program was launched  [&lt;ulink linkID="1566249" linkType="Reference"&gt;1566249&lt;/ulink&gt;]. By April 2016, the product was available in Australia [&lt;ulink linkID="1749489" linkType="Reference"&gt;1749489&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By April 2010, this program was launched  [&lt;ulink linkID="1566249" linkType="Reference"&gt;1566249&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By April 2016, the product was available in Australia [&lt;ulink linkID="1749489" linkType="Reference"&gt;1749489&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In April 2010, a multicenter, randomized, open trial  (&lt;ulink linkID="133902" linkType="Protocol"&gt;EudraCT 2009-018155-16&lt;/ulink&gt;; ALUMITES) was performed to assess the efficacy of subcutaneous immunotherapy with mites (Alustal Rapid) by acoustic rhinometry after nasal provocation in patients with allergic rhinitis [&lt;ulink linkID="1426523" linkType="Reference"&gt;1426523&lt;/ulink&gt;]. In June 2014, data were presented from a controlled, multicenter, phase IV study in 57 allergic rhinitis patients at the 2014 EAACI Congress in Copenhagen, Denmark. In the active group, significant improvements were observed in all symptoms (nasal obstruction, sneezing, rhinorrhoea, nasal itching) when compared with baseline and this improvement was not observed in control group [&lt;ulink linkID="1566249" linkType="Reference"&gt;1566249&lt;/ulink&gt;]. In June 2014, further data were presented at the same conference. In the active and control groups, the respective difference in total IgE between basal and 12 months visit was 27.5 and -55.4 kU/l. When compared with control group, specific IgG4 values for Der p1 and Der p2 increased significantly in active group [&lt;ulink linkID="1566247" linkType="Reference"&gt;1566247&lt;/ulink&gt;]. In  June 2014, further data were presented at the same conference. In the active group, an improvement in the quality of life score was observed at 12 months (1.2) from basal visit (2.6), while control groups had no significant improvement from basal visit (2.6) to 12 months (1.9)  [&lt;ulink linkID="1566243" linkType="Reference"&gt;1566243&lt;/ulink&gt;]. In June 2015, similar data were presented at the 2015 EAACI Congress in Barcelona, Spain [&lt;ulink linkID="1668611" linkType="Reference"&gt;1668611&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In February 2015, data   were presented from an environmental exposure chamber study (EEC) in 355 patients who received house dust mite tablets (500, 300 or 100 IR) or placebo at the 71st AAAAI Annual Meeting in Houston, TX. During peri-EEC challenge periods, incidence of asthma and related symptoms were higher; however, no difference was reported between the house dust mite and placebo groups. House dust mite treatment was generally well tolerated regardless of dose [&lt;ulink linkID="1641437" linkType="Reference"&gt;1641437&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;ADDITIONAL INFORMATION&lt;/subtitle&gt;In June 2015, the PDCO adopted a positive opinion on a full pediatric investigation plan (PIP) compliance check for Stallergenes allergen extract for allergic rhinitis [&lt;ulink linkID="1674993" linkType="Reference"&gt;1674993&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19274">Stallergenes SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate>2010-04-28T00:00:00.000Z</StatusDate><Source id="1426523" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19274">Stallergenes SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate>2016-04-07T00:00:00.000Z</StatusDate><Source id="1749489" type="PR"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1714787" linkType="reference" linkID="1714787"&gt;1714787&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1885196" number="EP-01908777" title="Mite fusion proteins"/><PatentFamily id="78919" number="EP-02388268" title="Recombinant Der p 2 expressed in &lt;i&gt;Pichia pastoris&lt;/i&gt; as a “natural-like” allergen for immunotherapy and diagnostic purposes"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endo International plc" id="1089706"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ares Life Sciences" id="1135234"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shionogi &amp; Co Ltd" id="19898"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Amsterdam" id="21182"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>